title: High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice.
abstract: When expression of more than one gene is required in cells, bicistronic or multicistronic expression vectors have been used. Among various strategies employed to construct bicistronic or multicistronic vectors, an internal ribosomal entry site (IRES) has been widely used. Due to the large size and difference in expression levels between genes before and after IRES, however, a new strategy was required to replace IRES. A self-cleaving 2A peptide could be a good candidate to replace IRES because of its small size and high cleavage efficiency between genes upstream and downstream of the 2A peptide. Despite the advantages of the 2A peptides, its use is not widespread because (i) there are no publicly available cloning vectors harboring a 2A peptide gene and (ii) comprehensive comparison of cleavage efficiency among various 2A peptides reported to date has not been performed in different contexts. Here, we generated four expression plasmids each harboring different 2A peptides derived from the foot-and-mouth disease virus, equine rhinitis A virus, Thosea asigna virus and porcine teschovirus-1, respectively, and evaluated their cleavage efficiency in three commonly used human cell lines, zebrafish embryos and adult mice. Western blotting and confocal microscopic analyses revealed that among the four 2As, the one derived from porcine teschovirus-1 (P2A) has the highest cleavage efficiency in all the contexts examined. We anticipate that the 2A-harboring cloning vectors we generated and the highest efficiency of the P2A peptide we demonstrated would help biomedical researchers easily adopt the 2A technology when bicistronic or multicistronic expression is required.
authors: Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju, Republic of Korea.
authors: Jin Hee
authors: JH
authors: Kim
authors: Sang-Rok
authors: SR
authors: Lee
authors: Li-Hua
authors: LH
authors: Li
authors: Hye-Jeong
authors: HJ
authors: Park
authors: Jeong-Hoh
authors: JH
authors: Park
authors: Kwang Youl
authors: KY
authors: Lee
authors: Myeong-Kyu
authors: MK
authors: Kim
authors: Boo Ahn
authors: BA
authors: Shin
authors: Seok-Yong
authors: SY
authors: Choi
references: Nat Methods. 2006 Mar;3(3):191-7
references: 16489336
references: Dev Dyn. 2007 Nov;236(11):3088-99
references: 17937395
references: Genes Dev. 1994 Jun 1;8(11):1311-23
references: 7926732
references: Virology. 2000 Dec 20;278(2):380-9
references: 11118361
references: Nat Protoc. 2007;2(5):1236-47
references: 17546019
references: J Gen Virol. 2001 May;82(Pt 5):1013-1025
references: 11297676
references: J Gen Virol. 1997 Jan;78 ( Pt 1):13-21
references: 9010280
references: J Gen Virol. 2001 May;82(Pt 5):1027-1041
references: 11297677
references: Genesis. 2007 Oct;45(10):625-9
references: 17941043
references: J Biol Chem. 2004 Jul 9;279(28):29409-17
references: 15138260
references: Nat Biotechnol. 2004 May;22(5):589-94
references: 15064769
references: Expert Opin Biol Ther. 2005 May;5(5):627-38
references: 15934839
references: J Gen Virol. 1991 Nov;72 ( Pt 11):2727-32
references: 1658199
references: Trends Biotechnol. 2006 Feb;24(2):68-75
references: 16380176
references: Genet Vaccines Ther. 2004 Sep 13;2(1):13
references: 15363111
references: Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):104-8
references: 20018670
references: Curr Gene Ther. 2002 Sep;2(3):355-78
references: 12189721
references: Biotechnol J. 2010 Feb;5(2):213-23
references: 19946875